Abstract： Objective： To observe the clinical effect of Biejiajian Pills combined with Tenofovir for hepatitis B cirrhosis in decompensated period with qi stagnation and blood stasis syndrome. Methods： A total of 98 cases of patients with hepatitis B cirrhosis in decompensated period with qi stagnation and blood stasis syndrome were selected and divided into the Biejiajian Pills group and the control group according to the random number table method，with 49 cases in each group. Six cases were excluded from the Biejiajian Pills group and seven cases were excluded from the control group. Finally， 43 cases in the Biejiajian Pills group and 42 cases in the control group were included. Both groups were given symptomatic treatments such as protecting the liver， reducing jaundice， and reducing portal vein pressure. On this basis， the control group was treated with Tenofovir Disoproxil Fumarate Tablets， and the Biejiajian Pills group was treated with Biejiajian Pills on the basis of the control group. Both groups were treated for six months. The clinical efficacy，levels of liver function indicators and liver fibrosis indicators，and chemokine receptor (CCR) positive expression rate were compared between the two groups， and the incidence of adverse reactions were recorded. Results： After treatment， the total effective rate was 95.35% in the Biejiajian Pills group，which was higher than that of 78.57% in the control group，the difference being significant (P＜ 0.05). The levels of aspartate aminotransferase (AST)， alanine aminotransferase (ALT)， and total bilirubin (TBil) in the two groups were decreased when compared with those before treatment (P＜0.05)， and the levels of AST， ALT， and TBil in the Biejiajian Pills group were lower than those in the control group (P＜ 0.05). The levels of fibrosis indicators including hyaluronic acid (HA)， laminin (LN)， type Ⅲ procollagen (PCⅢ)， and typeⅣcollagen (Ⅳ-C) in the two groups were decreased when compared with those before treatment (P＜0.05)，and the levels of HA，LN，PCⅢ，and Ⅳ-C in the Biejiajian Pills group were lower than those in the control group (P＜0.05). The positive expression rate of CCR4 and CCR6 in the two groups were decreased when compared with those before treatment (P＜0.05)，and the positive expression rate of CCR4 and CCR6 in the Biejiajian Pills group were lower than those in the control group (P＜0.05). The incidence of adverse reactions was 7.14% in the control group，and 9.30% in the Biejiajian Pills group，and there was no significant difference between the two groups (P＞0.05). Conclusion：Biejiajian Pills combined with Tenofovir has significant clinical efficacy in the treatment of hepatitis B cirrhosis in decompensated period with qi stagnation and blood stasis syndrome，which can effectively improve liver function and liver fibrosis indicators in patients. Its mechanism of action may be related to reducing CCR expression，and the treatment is safe.